Objective：To assess the therapeutic effects of dendritic cell-cytokine-induced killer（DC-CIK） cell immunotherapy with FOLFOX regimen on advanced colorectal cancer with diffusely hepatic metastasis. Methods：Totally 18 patients with advanced col－orectal cancer with diffuse hepatic metastasis from January 1，2008 to December 31，2010 were divided into 2 groups：FOLFOX group （group F） and DC+CIK+FOLFOX group（group DCF），9 patients in each group. Patients in group F were treated by FOLFOX regimen while those in group DCF were treated by DC-CIK cells immunotherapy with FOLFOX regimen. Results：In group F，0 patient attained complete remission（CR），2 patients attained partial remission（PR） with effective treatment rate of 28.6%. In group DCF，2 patients attained CR，5 patients attained PR with effective treatment rate of 87.5%，significantly higher than that of group F（P<0.05）. There was no significant difference in clinical benefit rate（CBR） between two groups. In the detection of immunological indexes，CD4+，CD8+ and value of CD4+/CD8+ were significantly raised after the treatment in group DCF，with statistically differences（P<0.05），while no sig－nificant difference in group F was observed. In group F，markers of gastrointestinal tumors were not significantly changed during the treatment，but were increased significantly after the treatment. In group DCF，markers of gastrointestinal tumors were decreased slowly during the treatment and were kept stable after the treatment. The 2-year survival rate was 0 in group F and was 33.3% in group DCF，with significantly statistical differences（P<0.05）. Conclusions：DC-CIK cell immunotherapy with FOLFOX regimen can prolong the survival time in the treatment of advanced colorectal cancer with diffusely hepatic metastasis and deserves clinical spread and ap－plication.